Hikal Stock Screener | Share Price & Fundamental Analysis
HIKAL
Pharmaceuticals
Share Price NSE
₹174.71
▲
9.53 (5.77%)
Share Price BSE
₹174.50
▲
9.45 (5.73%)
Track Hikal share price live with TickJournal's free stock screener.
Analyze Hikal share price history trends and compare 52-week high low
levels.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Hikal Market Cap
₹2,006.72 Cr.
HIKAL P/E Ratio (TTM)
-153.05
Hikal P/B Ratio
1.66
EPS (TTM)
₹7.36
Dividend Yield
0.50%
Debt to Equity
0.65
HIKAL 52 Week High
₹432.90
Hikal 52 Week Low
₹147.08
Operating Margin
8.00%
Profit Margin
-1.21%
HIKAL Revenue (TTM)
₹494.00
EBITDA
₹44.00
Net Income
₹-6.00
Total Assets
₹2,529.00
Total Equity
₹1,262.00
Hikal Share Price History - Stock Screener Chart
Screen HIKAL historical share price movements with interactive charts. Analyze price trends and patterns.
Hikal Company Profile - Fundamental Screener
Screen Hikal company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for HIKAL shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE475B01022
Hikal Balance Sheet Screener
Screen HIKAL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 2,529 | 2,487 | 2,386 | 2,213 | 1,913 | 1,768 | 1,686 | 1,542 | 1,380 | 1,275 |
| Current Assets | 995 | 967 | 939 | 964 | 879 | 775 | 830 | 690 | 577 | 467 |
| Fixed Assets | 1,365 | 1,071 | 948 | 880 | 713 | 735 | 713 | 634 | 668 | 623 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 477 | 543 | 591 | 376 | 323 | 355 | 327 | 312 | 334 | 337 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 1,262 | 1,188 | 1,134 | 1,068 | 933 | 817 | 756 | 669 | 605 | 564 |
| Share Capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 16 | 16 | 16 |
| Reserves & Surplus | 1,238 | 1,163 | 1,109 | 1,043 | 909 | 792 | 732 | 653 | 589 | 547 |
Hikal Income Statement Screener - Profit & Revenue Analysis
Screen Hikal income statement and profit fundamentals.
Analyze HIKAL quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Hikal share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 494 | 318 | 372 | 551 | 443 | 451 | 404 | 513 | 439 | 432 | 387 | 538 | 541 | 558 | 375 |
| Expenses | 450 | 311 | 355 | 429 | 376 | 378 | 349 | 420 | 383 | 377 | 338 | 457 | 466 | 489 | 356 |
| EBITDA | 44 | 7 | 17 | 122 | 67 | 73 | 56 | 94 | 56 | 55 | 49 | 81 | 75 | 69 | 19 |
| Operating Profit % | 8.00% | 2.00% | 4.00% | 22.00% | 14.00% | 16.00% | 14.00% | 18.00% | 13.00% | 12.00% | 13.00% | 15.00% | 14.00% | 12.00% | 4.00% |
| Depreciation | 41 | 41 | 39 | 38 | 33 | 32 | 32 | 32 | 29 | 29 | 28 | 27 | 28 | 27 | 27 |
| Interest | 16 | 15 | 17 | 18 | 19 | 19 | 20 | 15 | 14 | 13 | 14 | 13 | 13 | 11 | 11 |
| Profit Before Tax | -9 | -47 | -30 | 68 | 24 | 25 | 7 | 47 | 22 | 17 | 10 | 49 | 36 | 33 | -12 |
| Tax | -3 | -12 | -8 | 18 | 7 | 7 | 2 | 13 | 6 | 4 | 3 | 13 | 9 | 8 | -3 |
| Net Profit | -6 | -35 | -22 | 50 | 17 | 18 | 5 | 34 | 16 | 13 | 7 | 36 | 26 | 25 | -9 |
| EPS | -0.48 | -2.83 | -1.82 | 4.07 | 1.39 | 1.48 | 0.41 | 2.76 | 1.31 | 1.02 | 0.56 | 2.92 | 2.14 | 2.01 | -0.72 |
Hikal Cash Flow Screener - Liquidity Fundamentals
Screen HIKAL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 280 | 187 | 315 | 294 | 229 | 285 | 186 | 139 | 164 | 186 |
| Investing Activities | -137 | -174 | -292 | -284 | -156 | -164 | -125 | -110 | -102 | -64 |
| Financing Activities | -144 | -27 | -8 | -6 | -97 | -101 | -55 | -25 | -63 | -124 |
| Net Cash Flow | 0 | -14 | 15 | 4 | -24 | 20 | 6 | 4 | -2 | -2 |
Hikal Shareholding Pattern Screener
See Hikal shareholding pattern with promoter, FII, and DII holdings.
Check Hikal promoter holding and ownership changes for HIKAL on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% | 68.85% |
| FII Holding | 5.69% | 5.36% | 4.23% | 2.30% | 6.55% | 6.67% | 6.78% | 6.06% |
| DII Holding | 3.80% | 4.02% | 5.16% | 7.05% | 3.53% | 3.17% | 3.58% | 3.48% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 16.57% | 16.75% | 16.66% | 16.77% | 16.45% | 16.31% | 15.81% | 16.64% |
| Other Holding | 5.08% | 5.02% | 5.10% | 5.02% | 4.62% | 5.01% | 4.99% | 4.97% |
| Shareholder Count | 68,907 | 71,391 | 73,404 | 74,117 | 71,840 | 70,978 | 71,912 | 71,801 |
Hikal Share Dividend Screener - Share Yield Analysis
Check Hikal dividend history with payout and yield data.
View Hikal dividend details including ex-dates and amounts for HIKAL stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.80 | 0.54% |
| 2024-March | ₹1.20 | 0.30% |
| 2023-March | ₹1.20 | 0.45% |
| 2022-March | ₹1.60 | 0.57% |
| 2021-March | ₹2.00 | 0.50% |
| 2020-March | ₹1.20 | 0.84% |
| 2019-March | ₹1.20 | 1.72% |
| 2018-March | ₹1.20 | 0.69% |
| 2017-March | ₹1.20 | 0.87% |
Hikal Stock Index Membership
See which indices include Hikal stock.
Check HIKAL index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT
Hikal Market Events Screener - Corporate Actions
Get Hikal corporate actions including splits, bonuses, and buybacks.
Check Hikal stock events that may affect HIKAL share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 17.36% | ||
| Annual General Meeting | NA | -14.46% | ||
| Dividend | ₹ 0.60 /share | 9.00% | ||
| Dividend | ₹ 0.80 /share | -37.12% | ||
| Dividend | ₹ 0.60 /share | 12.32% | ||
| Dividend | ₹ 0.40 /share | -2.48% | ||
| 2026-02-17 | 2026-02-17 | Dividend | ₹ 0.20 /share | 10.78% |
| 2026-02-11 | 2026-02-11 | Quarterly Result Announcement | NA | -3.28% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | -0.76% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | -6.81% |
| 2025-05-14 | 2025-05-14 | Quarterly Result Announcement | NA | 2.48% |
| 2025-02-07 | 2025-02-08 | Dividend | ₹ 0.60 /share | 5.04% |
| 2025-02-04 | 2025-02-04 | Quarterly Result Announcement | NA | 6.12% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | 1.74% |
| 2024-02-20 | 2024-02-20 | Dividend | ₹ 0.60 /share | -2.64% |
Hikal Competitors Screener - Peer Comparison
Screen HIKAL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 405,176 | 37.12 | 54,729 | 9.71% | 10,980 | 37.98 |
| Divis Laboratories | 154,569 | 62.72 | 9,712 | 18.67% | 2,191 | 33.24 |
| Torrent Pharmaceuticals | 135,696 | 59.42 | 11,539 | 6.99% | 1,911 | 32.75 |
| Lupin | 104,124 | 22.29 | 22,910 | 13.74% | 3,306 | 47.35 |
| Dr Reddys Laboratories | 101,192 | 18.40 | 33,741 | 16.73% | 5,725 | 39.36 |
| Cipla | 96,837 | 21.27 | 28,410 | 7.12% | 5,291 | 26.86 |
| Zydus Life Science | 86,929 | 17.30 | 23,511 | 18.55% | 4,615 | 41.42 |
| Mankind Pharma | 83,263 | 45.73 | 12,744 | 20.90% | 2,007 | 41.40 |
| Aurobindo Pharma | 77,647 | 22.27 | 32,346 | 9.43% | 3,484 | 64.38 |
| Alkem Laboratories | 62,455 | 25.95 | 13,458 | 3.70% | 2,216 | 42.54 |
Hikal Company Announcements - News Screener
Screen HIKAL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-03-25 | Closure of Trading Window | - |
| 2026-02-18 | Intimation Under Regulation 7 (2) Of SEBI Prohibition Of Insider Trading Regulations 2015 | - |
| 2026-02-18 | Disclosure under Regulation 30A of LODR | - |
| 2026-02-18 | Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011 | - |
| 2026-02-18 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 | - |
| 2026-02-18 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-02-17 | Announcement Under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-02-12 | Communication To Shareholders: Interim Dividend For FY 2025-26- Intimation Tax Deduction At Source (TDS) Withholding Tax On Interim Dividend For FY 2025-26 . | - |
| 2026-02-12 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-02-11 | Intimation Of Amendment To The Code Of Internal Procedures And Conduct For Regulating Monitoring And Reporting Trading By Designated Persons Of The Company | - |
| 2026-02-11 | Announcement under Regulation 30 (LODR)-Dividend Updates | - |
| 2026-02-11 | Corporate Action-Board approves Dividend | - |
| 2026-02-11 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-02-11 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-02-11 | Board Meeting Outcome for Outcome Of The Board Meeting | - |
| 2026-02-11 | Results-Financial Results For December 31 2025 | - |
| 2026-02-04 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-04 | Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended December 31 2025 | - |
| 2026-01-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |